Recombinant Human CX3CL1/Fractalkine (FKN)

Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium¹ that mediates attachment and firm adhesion of T cells, monocytes and NK cells.² FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.³ FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).⁴

qhhgvt kcnitcskmt skipvallih yqqnqascgk raiiletrqh rlfcadpkeq wvkdamqhld rqaaaltrng

Gln25

Lyophilized

The predicted molecular weight of Recombinant Human Fractalkine is Mr 8.5 kDa.

8.5

This recombinant protein was lyophilized from a 0.2 μm filtered solution in 35% acetonitrile (CH₃CN) and 0.1% trifluoroacetic acid (TFA).

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.

Next Day Ambient

1. Patel, DD. et al. (1998) J Exp Med. 188: 1413
2. Hwang, ST. et al. (1999) Eur J Immunol. 29: 2551
3. Muller, GA. et al. (2008) Z Rheumatol. 67: 424
4. Mori, M. et al. (2005) Int J Oncol. 26: 41